• 1
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 16778
  • 2
    Brown JS, Grady D, Ouslander JG, Herzog AR, Varner RE, Posner SF, for the Heart & Estrogen/Progestin Replacement Study (HERS) Research Group. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Obstet Gynecol 1999; 94: 6670
  • 3
    Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how do we manage them? A population-based prevalence study. BJU Int 2001; 87: 7606
  • 4
    Feneley RCL, Shepherd AM, Powell PH, Blannin J. Urinary incontinence: prevalence and needs. Br J Urol 1979; 51: 4936
  • 5
    Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55 (Suppl. 5A): 3346
  • 6
    Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50 (Suppl. 6A): 906
  • 7
    Jonas U, Höfner K, Madersbacher H et al. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 1997; 15: 14451
  • 8
    Abrams P, Freeman R, Anderström C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81: 80110
  • 9
    Drutz H, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J 1999; 10: 2839
  • 10
    Larsson G, Hallén B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 1999; 53: 9908
  • 11
    Millard R, Tuttle J, Moore K et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999; 161: 15515
  • 12
    Van Kerrebroeck P, Kreder K, Jonas U et al. Tolterodine once-daily. superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001; 57: 41421
  • 13
    Chancellor M, Freedman S, Mitcheson HD, Antoci J, Primus G, Wein A. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest 2000; 19: 8391
  • 14
    Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmacother 2000; 11: 1327
  • 15
    Ward K, Hilton P, on behalf of the United Kingdom and Ireland Tension-free Vaginal Tape Trial Group. Prospective multicentre randomised trial of tension-free vaginal tape and colposuspension as primary treatment for stress incontinence. BMJ 2002; 325: 6773
  • 16
    Kreder K, Pleil AM, Reese PR et al. Effects of long-term tolterodine treatment on social and psychological aspects of health-related quality of life in overactive bladder patients. J Urol 2002; 167 (Suppl. 4): 29 (Abstract)
  • 17
    Hetta J. The impact of sleep deprivation caused by nocturia. BJU Int 1999; 84 (Suppl. 1): 278
  • 18
    Fonda D, Benvenuti F, Castleden M et al. Management of incontinence in older people. In AbramsP, KhouryS, WeinA eds, Incontinence. Proceedings of the 1st International Consultation on Incontinence; Monaco, June 28–July 1 1998. Plymouth: Health Publication Ltd, 1999: 73173